|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.116 EUR | -2.45% |
|
-5.74% | -68.61% |
| 28/06 | AB Science: negative CHMP opinion for masitinib in ALS | CF |
| 03/06 | AB Science: share price falls on resumption of trading | CF |
AB Science S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 0.97 million compared to EUR 0.958 million a year ago. Net loss was EUR 10.05 million compared to EUR 13.62 million a year ago.
Basic loss per share from continuing operations was EUR 0.2 compared to EUR 0.29 a year ago. Diluted loss per share from continuing operations was EUR 0.2 compared to EUR 0.29 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -68.61% | 7.07Cr | |
| +7.39% | 7.21TCr | |
| +15.93% | 904.53Cr | |
| -22.81% | 440.44Cr | |
| +17.59% | 439.23Cr | |
| +25.93% | 393.64Cr | |
| +4.64% | 210Cr | |
| +9.09% | 197.11Cr | |
| -36.86% | 187.45Cr | |
| -0.50% | 164.41Cr |
AB SCIENCE 
